hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06385496 id: NCI-2024-01145 id: NCI-2024-01145 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAY131-L id: EAY131-L type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAY131-L type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) overallStatus: ACTIVE_NOT_RECRUITING date: 2017-03-12 date: 2024-12-31 date: 2024-12-31 date: 2024-04-26 date: 2024-04-26 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called mTOR mutations. MLN0128 (TAK-228) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. conditions: Advanced Lymphoma conditions: Advanced Malignant Solid Neoplasm conditions: Refractory Lymphoma conditions: Refractory Malignant Solid Neoplasm conditions: Refractory Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Magnetic Resonance Imaging name: Sapanisertib measure: Objective response rate (ORR) measure: Overall survival (OS) measure: 6-month progression free survival (PFS) measure: Progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ECOG-ACRIN Cancer Research Group city: Philadelphia state: Pennsylvania zip: 19103 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06385483 id: NCI-2024-01125 id: NCI-2024-01125 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAY131-A type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAY131-A type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) overallStatus: ACTIVE_NOT_RECRUITING date: 2015-08-11 date: 2024-12-06 date: 2024-12-06 date: 2024-04-26 date: 2024-04-26 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II MATCH treatment trial tests how well afatinib works in treating patients with cancer that has certain genetic changes. Afatinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the EGFR gene. It works by blocking the action of mutated EGFR that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. conditions: Advanced Lymphoma conditions: Advanced Malignant Solid Neoplasm conditions: Refractory Lymphoma conditions: Refractory Malignant Solid Neoplasm conditions: Refractory Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Afatinib name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Echocardiography name: Magnetic Resonance Imaging name: Radionuclide Imaging measure: Objective response rate (ORR) measure: Overall survival (OS) measure: 6-month progression free survival (PFS) measure: Progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ECOG-ACRIN Cancer Research Group city: Philadelphia state: Pennsylvania zip: 19103 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06385470 id: HSEARS20231112001 briefTitle: Treatment of Cantonese Speakers With Childhood Apraxia of Speech overallStatus: RECRUITING date: 2024-04-15 date: 2024-08-01 date: 2025-02-01 date: 2024-04-26 date: 2024-04-26 name: The Hong Kong Polytechnic University class: OTHER name: University of Vermont name: The University of Hong Kong briefSummary: The proposed study aims to investigate the efficacy of the Dynamic Temporal and Tactile Cueing treatment in Cantonese-English bilingual speakers with childhood apraxia of speech. conditions: Childhood Apraxia of Speech studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 4 type: ESTIMATED name: Dynamic Temporal and Tactile Cueing treatment measure: Phonemes accuracy measure: Stress accuracy measure: Tone accuracy sex: ALL minimumAge: 3 Years maximumAge: 11 Years stdAges: CHILD facility: The Hong Kong Polytechnic University status: RECRUITING city: Kowloon country: Hong Kong name: Min Ney Wong, PhD role: CONTACT phone: +852 2766 7268 email: min.wong@polyu.edu.hk lat: 22.31667 lon: 114.18333 hasResults: False
nctId: NCT06385457 id: 24-2933 briefTitle: The Effects of Mindhelper on Young People's Well-being, Psychological Functioning, and Intentions to Help-seeking overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2025-01-31 date: 2025-01-31 date: 2024-04-26 date: 2024-04-26 name: University of Southern Denmark class: OTHER name: TrygFonden, Denmark name: Danske Regioner name: Jascha Fonden name: Centre for Digital Psychiatry, Mental Health Services in the Region of Southern Denmark briefSummary: In this study the investigators will evaluate the effectiveness of Mindhelper.dk, which is the most comprehensive online youth mental health promotion service in Denmark.
A minimum of 9,426 young people aged 15 to 25 will be recruited through social media and invited to participate in the study. When responding to the baseline questionnaire participants will be randomized to either the intervention or control group. The intervention group will receive information about Mindhelper.dk and inspiration on how to use Mindhelper through text-messages during the study period. The control group does not receive information about Mindhelper.dk, until after completion of the last follow-up questionnaire.
The investigators expect a small, positive effect on participants well-being and psychological functioning in intervention groups as compared to the control group. conditions: Mental Health Issue conditions: Well-Being conditions: Adolescents conditions: Young Adults conditions: Online Intervention conditions: Internet-Based Intervention conditions: Randomized Controlled Trial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study.
Analyses of data and interpretation of results will be done masked. whoMasked: INVESTIGATOR count: 9426 type: ESTIMATED name: Mindhelper- A national youth mental health promotion website measure: General well-being measure by "The Well-Being Index WHO-5" (WHO5) measure: Psychological functioning, measure by "The Short Warwick-Edinburgh Mental Well-Being Scale" (SWEMWBS). measure: Intentions to help-seeking measure: Body Appreciation measured by the "2-items Short forms of the Body Appreciation Scale-2" (2-item BAS-2SF). sex: ALL minimumAge: 15 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: National Institute of Public Health (NIPH), University of Southern Denmark city: Copenhagen state: Copenhagen K zip: 1455 country: Denmark name: Sofie H Hoffmann role: CONTACT phone: 65 50 77 34 phoneExt: +45 email: sohh@sdu.dk name: Lau C Thygesen role: CONTACT phone: 65 50 77 71 phoneExt: +45 email: lct@sdu.dk lat: 55.67594 lon: 12.56553 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-04-22 uploadDate: 2024-04-22T08:21 filename: SAP_000.pdf size: 353976 hasResults: False
nctId: NCT06385444 id: 2024-HS-020 briefTitle: IVF Failure and Pregnancy Loss on Couples' Psychological Stress overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-06-01 date: 2024-04-26 date: 2024-04-26 name: The First Hospital of Jilin University class: OTHER briefSummary: The goal of this observational study is to learn about The purpose of this study was to compare the psychological differences between couples after IVF transplant failure and IVF pregnancy loss, including the differences in anxiety, depression, stress and post-traumatic stress between women and their spouses. The main question it aims to answer is:
What are the psychological effects of IVF implantation failure and IVF pregnancy loss on women and the psychological differences between couples? Participants already taking IVF as part of their regular medical care will answer online survey questions about their joint pain for 1 years. conditions: Fertilization in Vitro conditions: Pregnancy Loss conditions: Psychological Stress conditions: Post-traumatic Stress studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED measure: As the number of failed IVF implants increases, does it increase the difference in anxiety and depression between couples? measure: As the number of failed IVF implants increases, does it increase the difference in fertility stress between couples? measure: Does pregnancy loss after IVF transplantation have a differential effect on anxiety and depression between couples? measure: Does pregnancy loss after IVF transplantation have a differential effect on post-traumatic stress responses between couples? sex: ALL minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT facility: the first hospital of Jilin University city: Chang chun state: Jilin zip: 130000 country: China name: Qi Xi, doctorate role: CONTACT phone: 15804303801 email: xiqi@jlu.edu.cn lat: 42.74694 lon: 126.24667 hasResults: False
nctId: NCT06385431 id: Charm briefTitle: Obeservational Cohort for Evaluating Future Cardiovascular Disease With High Metabolic Risks acronym: Charm overallStatus: NOT_YET_RECRUITING date: 2024-04-28 date: 2026-04-30 date: 2026-04-30 date: 2024-04-26 date: 2024-04-26 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: Cardiovascular and metabolic diseases refer to a large category of cardiovascular diseases accompanied by a series of metabolic disorders (including dyslipidemia, obesity, abnormal glucose tolerance, diabetes, hypertension, thyroid dysfunction, etc.), which is the primary cause of death and disease burden of Chinese residents.The number of deaths from atherosclerotic cardiovascular disease (ASCVD) in China is about 2.4 million, accounting for 61% of the total cardiovascular deaths, accounting for more than 40% of the all-cause deaths. In Chinese patients with coronary heart disease, 52.9% are complicated with diabetes.Despite the 1.1 million coronary stents implanted in China, there has been no reduction in cardiovascular mortality, which highlights the importance of threshold advancement and the management of metabolic risk factors.
In recent years, the new concept of cardiovascular and metabolic diseases has been actively promoted at home and abroad, and the focus of prevention and treatment strategy of cardiovascular and metabolic diseases has been called for.The project proposed the concept of co-treatment of metabolic diseases based on disorders of blood pressure regulation, disorders of glucose metabolism and disorders of lipid metabolism. Subjects eligible for cardiovascular and metabolic diseases were screened, their past medical records were registered, education and diagnosis and treatment management were conducted. conditions: Metabolic Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 8000 type: ESTIMATED name: observational study measure: incidence rate of cardiovascular and metabolic diseases measure: treatment rate of cardiovascular and metabolic diseases measure: control rate of cardiovascular and metabolic diseases. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385418 id: WST-CRC-202404 briefTitle: Fluorouracil Treatment Via Colon for Colorectal Cancer overallStatus: RECRUITING date: 2024-05-01 date: 2028-05-01 date: 2029-05-01 date: 2024-04-26 date: 2024-04-26 name: The Second Hospital of Nanjing Medical University class: OTHER briefSummary: Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive hydrogel presents a promising carrier for 5-FU to address challenges encountered with traditional administration methods. We propose an integrated approach utilizing colonic transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the feasibility, safety, and efficacy of this approach for treating CRC. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Colonic local administration of fluorouracil with enhanced adhesion measure: Objective response rate (according to RECIST1.1, investigator assessment) measure: Progression-free survival measure: Overall survival measure: Disease control rate (according to RECIST1.1, investigator assessment) measure: Drop period to ensure operation resection measure: Converted resection rate measure: Actual R0 resection rate measure: The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210011 country: China name: Faming Zhang, MD, PhD role: CONTACT lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06385405 id: 2024y0423 briefTitle: Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-26 date: 2024-04-26 name: Shanghai Mental Health Center class: OTHER name: National Natural Science Foundation of China name: Shanghai Municipal Science and Technology Commission name: Shanghai Jiao Tong University School of Medicine briefSummary: This study will focus on the hypothesis that repetitive transcranial magnetic stimulation (TMS) based on EEG personalized modulation may be more effective in promoting symptomatic relief of major depressive disorder (MDD), and will rely on the platform of neuroimaging and function brain imaging of Shanghai Mental Health Center (SMHC), an authoritative institution in the field of mental health. We will eventually facilitate optimization of physical therapy for major depressive disorder (MDD). conditions: Major Depressive Disorder (MDD) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: To test the hypothesis that repetitive transcranial magnetic stimulation based on individualized EEG modulation may be more effective in promoting symptomatic relief of major depressive disorder (MDD), patients were tested in a parallel controlled trial.During the treatment period, patients will be randomly grouped into the precision group, which will be treated with rTMS based on personalized modulation of EEG data, and the conventional group, which will be treated with TMS at a frequency of 10 Hz to stimulate the left dorsolateral prefrontal cortex (DLPFC). primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment name: 10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC) measure: the effective rate measure: complete remission rate measure: alpha band spectral connectivity in electroencephalogram (EEG) parameters measure: Evaluation of therapeutic effect sex: ALL minimumAge: 16 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Mental Health Center city: Shanghai state: Shanghai zip: 200030 country: China name: TianHong Zhang, Doctor role: CONTACT phone: 13127577024 email: zhang_tianhong@126.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06385392 id: A23-354 briefTitle: Continuous Wearable Monitor for the Detection and Release of Freezing of Gait. overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-05 date: 2024-04-26 date: 2024-04-26 name: HealthPartners Institute class: OTHER briefSummary: The proposed system (haptic module and insole device) for daily in-community use that detects the occurrence of freezing of gait (FOG) in people with Parkinson's disease (PD). and triggers external cueing stimuli to unfreeze the individual. The purpose of the overall Phase II study is to: (1) Develop a production ready system, (2) Develop a companion mobile app for the proposed system and refine previously developed FOG detection algorithms, and (3) Validate the proper operation of the system and demonstrate its efficacy through lab and in-community testing. This study will focus on validating the system and demonstrating efficacy through in-community testing. conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 36 type: ESTIMATED name: Haptic module and insole device measure: To validate the haptic module and insole device system and evaluate its efficacy with an in-community clinical trial. sex: ALL minimumAge: 45 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Struthers Parkinson's Center city: Golden Valley state: Minnesota zip: 55427 country: United States name: Research Coordinator role: CONTACT phone: 651-495-6363 email: ClinicalTrials@HealthPartners.com lat: 45.00969 lon: -93.34912 facility: HealthPartners Neuroscience Center city: Saint Paul state: Minnesota zip: 55130 country: United States name: Clinical Trial Coordinator role: CONTACT phone: 651-495-6363 email: ClinicalTrials@HealthPartners.com lat: 44.94441 lon: -93.09327 hasResults: False
nctId: NCT06385366 id: GS_NP1 briefTitle: Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-05-06 date: 2025-06-06 date: 2024-04-26 date: 2024-04-26 name: Gene Solutions class: INDUSTRY name: Medical Genetics Institute (MGI) briefSummary: This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk pregnancy of PE, SPB, and GDM in Vietnam. conditions: Pregnant With Complication conditions: Preeclampsia conditions: Preterm Birth conditions: Gestational Diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1105 type: ESTIMATED measure: Characteristics of pregnant women at 1st trimester (9-13 weeks 6 days of gestation) measure: Characteristics of pregnant women at recruitment measure: Define the significant differences between cases and controls measure: The development of learning machine models measure: Evaluation of the developed models sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385353 id: 2022-CHITS-003 id: 2023-A02652-43 type: OTHER domain: ID-RCB number briefTitle: DVT Burden and the Risk of Post-thrombotic Syndrome acronym: DVT-Burden overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-06 date: 2024-04-26 date: 2024-04-26 name: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer class: OTHER name: Assistance Publique Hopitaux De Marseille name: F-CRIN INNOVTE Research Network briefSummary: Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT), with major consequences for patient quality of life and cost of management. Identifying patients at high risk of developing PTS could be useful for its prevention and may lead to more appropriate therapeutic strategies to reduce its incidence and severity.
Prognostic tools for predicting risk are very useful for choosing the optimum treatment and improving patient management and are a preliminary step before developing predictive models useful for determining sensitivity to treatment. At present, although several prognostic markers and models have been proposed, it is still difficult to predict who will develop a PTS or a moderate to severe PTS. The development of PTS is multifactorial and depends largely on the extent and severity of venous obstruction which supports the theory of thrombosis burden (DVT-Burden) as a potential prognostic marker for PTS. It therefore seems important to study the association between thrombosis burden and the occurrence of PTS.
The Venous Volumetric Index or VVI (Ouriel 1999) will be used for quantifying DVT-Burden. The VVI was constructed by calculating the volume from the diameter and length of 14 venous segments from the calf veins to the inferior vena cava. The VVI has been validated for its ability to discriminate between symptomatic and asymptomatic DVT and has shown superior performance to other methods for quantifying DVT.
nctId: NCT06385340 id: CentroDerm_LRP22003 briefTitle: Investigation of the Effect of Lipikar Baume AP+M overallStatus: NOT_YET_RECRUITING date: 2024-04-23 date: 2024-09-30 date: 2024-10-31 date: 2024-04-26 date: 2024-04-26 name: CentroDerm GmbH class: NETWORK briefSummary: Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme The purpose of this study is to observe the skin barrier function, transepidermal water loss and microbial changes in study participants with actinic field damage of both arms.
The study design consists in 4-week evaluation period, with 2 visits per subject: Screening/Baseline (Day 0, Day 28 (end of Lipikar Baume AP+M application)). conditions: Actinic Keratoses studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It's a randomized, evaluator blinded, intra-individual controlled study conducted in one center in Germany, in adult subjects having AK (grade I to III) lesions on the forearms and back of hands and meeting specific inclusion/exclusion criteria. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: INVESTIGATOR count: 20 type: ESTIMATED name: Lipikar Baume AP+M measure: Skin hydration measured by Corneometrie measure: Transepidermal water loss measured by Tewameter® measure: Aktinic keratosis area and severity index (AKASI) measure: S. aureus colonization and S. epidermidis colonization (application area) measure: Subjects's skin aspect measure: Absolute lesion count by application site measure: Olsen Grade evaluation: percentage of lesion with improvement at least 1 grade at D28 by application site measure: Number of new lesions on application area over the study period by application site measure: Symptom severity score: percentage across individual scores at each visit by application site measure: modified Treatment Satisfaction Questionnaire for Medication-9 (mTSQM-9) measure: Compliance (percentage of subjects using topical agents at all intended days, 90% of days or 75% of days) measure: Pictures at all time points sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False